News

23

Jul, 2021

CARMA study publishes article in Journal of International AIDS Society

Tags: , ,

The CARMA team in the EPIICAL consortium have just published the article Early ART initiation during infancy preserves natural killer cells in young European adolescents living with HIV (CARMA cohort) in the Journal of International AIDS Society. HIV infection causes pathological changes in the natural killer cell compartment, a type of white blood cell with enzymes that kill cells infected with a virus. Through antiretroviral therapy (ART), this compartment can be partially restored. The CARMA team looked into the characteristics and function of natural killer cells in children born with HIV and […]

READ MORE

16

Jul, 2021

New findings from the ODYSSEY trial confirm superiority of dolutegravir-based ART in younger children

Tags: , ,

WHO welcomes new findings presented today at International Pediatric HIV Workshop on the superiority of dolutegravir (DTG)-based regimens in young children. Children living with HIV continue to be left behind by the global AIDS response. In 2020, only 54% of the 1.7 million children living with HIV received antiretroviral therapy in 2020 compared to 74% among adults living with HIV. Among the focus countries, only 40% of children living with HIV (or 74% of children receiving antiretroviral therapy) achieved viral suppression in 2020. The ODYSSEY trial, a multi-country randomised trial […]

READ MORE

15

Jul, 2021

Penta at IAS and the International Workshop on HIV Pediatrics 2021

Tags: , ,

This year, at the International Workshop on HIV Pediatrics and IAS our ODYSSEY and SMILE studies and EPIICAL will be presenting abstracts in various sessions.   The International Workshop on HIV Pediatrics 2021 will be taking place from the 16th to the 17th of July 2021. It is considered to be the only meeting entirely devoted to research in the prevention and treatment of HIV infections in infants, children, and adolescents, making it the premier forum for the world’s leading researchers. Find out more about the workshop here. Penta presentations: […]

READ MORE

25

Mar, 2021

Advancing the delivery of HIV Care

Tags:

On June 21-22, the International Workshop on Innovation in the delivery of HIV care will take place virtually. This is an important workshop highlighting the need for flexibility and innovation when it comes to caring for people living with HIV, to circumvent occurrences beyond our control that could negatively impact the type of care and treatment that healthcare workers provide. Participants will have the chance to share and learn how their peers provide care in terms of the innovative measures they introduced due to COVID-19, how they deliver HIV Care […]

READ MORE

22

Mar, 2021

Because we all have to grow up”: supporting adolescents in Uganda to develop core competencies to transition towards managing their HIV more independently

Tags:

Authors: Chloe Lanyon, Janet Seeley, Stella Namukwaya, Victor Musiime, Sara Paparini, Helen Nakyambadde, Christine Matama, Anna Turkova, Sarah Bernays   Published in: Journal of International Aids Society   Abstract Introduction: Sustaining optimal adherence is the major challenge facing adolescents living with HIV (ALHIV), particularly in low-resource settings, where “second-line” is often the last accessible treatment option. We explored the knowledge and skills adolescents need in order to maintain improved adherence behaviours, and the specific ways clinicians and caregivers may support young people to do so more independently. Methods: We conducted individual, in-depth interviews with 20 ALHIV aged 10 to 18 […]

READ MORE

12

Mar, 2021

Sharing our understanding of the immune response of children living with HIV

Tags: , , ,

EPIICAL is proud to have presented four abstracts at the CROI conference this year, sharing updated information on viral decay and the immune response of children living with HIV who begin treatment early in life.   EFFECT OF HIV ON IMMUNE ACTIVATION AND EXHAUSTION IN CD4 AND CD8 T CELLS IN INFANTS Stefano Rinaldi, Vinh B. Dinh, Suresh Pallikkuth, Lesley D. Armas, Nadia Sitoe, Rajendra Pahwa, Nicola Cotugno, Paula Vaz, Paolo Palma, MariaGrazia Lain, Savita G. Pahwa DYNAMICS OF INTACT PROVIRAL SEQUENCES IN EARLY TREATED HIV-1 CLADE C–INFECTED INFANTS Catherine […]

READ MORE

11

Mar, 2021

ODYSSEY trial finds new drug is better for treating children living with HIV

Tags: , , ,

The anti-HIV drug Dolutegravir improves outcomes for children with HIV infection when given in a 3-drug combination. These results come from the ODYSSEY trial which was presented yesterday at the Conference on Retroviruses and Opportunistic Infections. Dolutegravir has a number of potential advantages, including: Few drug-to-drug interactions, making it easier to use when treating people who need treatment for other conditions such as tuberculosis High potency at a low milligram dose, meaning tablets can be small High genetic barrier to resistance Low cost Trials of dolutegravir in combination treatments in […]

READ MORE

19

Feb, 2021

ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing

Tags: , ,

Authors: Cecilia L. Moore, Anna Turkova , Hilda Mujuru , Adeodata Kekitiinwa, Abbas Lugemwa, Cissy M. Kityo, Linda N. Barlow-Mosha, et al, ODYSSEY trial team Published in: BMC Infectious Diseases   Background: Dolutegravir (DTG)-based antiretroviral therapy (ART) is highly effective and well-tolerated in adults and is rapidly being adopted globally. We describe the design of the ODYSSEY trial which evaluates the efficacy and safety of DTG-based ART compared with standard-of-care in children and adolescents. The ODYSSEY trial includes nested pharmacokinetic (PK) sub-studies which evaluated pragmatic World Health Organization (WHO) weight-band-based […]

READ MORE
NEWSLETTER

We would like to update you on our recent activities

Subscribe

No thanks, I’m not interested!